SCHEMBL2392382

SCHEMBL2392382

COc1cc2[nH]c3ncnc(N4CCNCC4)c3c2cc1OC

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP2K7 O14733 3/20 0.58
AURKA O14965 2/20 0.56
KIT P10721 2/20 0.52
PDGFRA P16234 1/20 0.52
CDK1 P06493 1/20 0.49
MAP2K6 P52564 1/20 0.49
ENPP1 P22413 1/20 0.49
ALDH1A1 P00352 5/20 0.48
KDM4E B2RXH2 4/20 0.48
HSD17B10 Q99714 3/20 0.48
USP2 O75604 3/20 0.47
MAPT P10636 3/20 0.47
HPGD P15428 3/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
TSHR P16473 1/20 0.47
ALOX12 P18054 1/20 0.47
PDE10A Q9Y233 1/20 0.47
LMNA P02545 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4092436 0.87 TLR9 (0.52) MAP2K7AURKAKITPDGFRAENPP1
SCHEMBL5125361 0.83 HRH4 (0.55) KDM4EHSD17B10USP2MAPTHPGD
SCHEMBL16019441 0.82 BRD4 (0.69) BRD4
SCHEMBL3126375 0.82 PDGFRA (0.62) MAP2K7AURKAKITPDGFRACDK1
SCHEMBL3126359 0.82 PDGFRA (0.56) MAP2K7AURKAKITPDGFRACDK1
SCHEMBL13790491 0.81 AURKA (0.52) MAP2K7AURKAKITPDGFRACDK1
SCHEMBL19593943 0.81 MAP2K7 (0.43) MAP2K7AURKAKITPDGFRACDK1
SCHEMBL20581274 0.80 SPIN1 (0.59) MAP2K7KITENPP1
SCHEMBL20580814 0.79 SPIN1 (0.58) MAP2K7KITENPP1
SCHEMBL12255552 0.78 ENPP1 (0.49) MAP2K7AURKAKITPDGFRAENPP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8999988-B2 Protein kinase inhibitors ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2015-04-07 US disclosed
US-20130302303-A1 PROTEIN KINASE INHIBITORS ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA 2013-11-14 US disclosed
US-8552018-B2 Substituted tricyclic compounds as protein kinase inhibitors ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2013-10-08 US disclosed
US-20110212929-A1 Protein Kinase Inhibitors ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA 2011-09-01 US disclosed
EP-1678166-B1 PROTEIN KINASE INHIBITORS UNIV ARIZONA (US) 2009-07-29 EP disclosed
US-20090143399-A1 Protein Kinase Inhibitors ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2009-06-04 US disclosed
US-20090099165-A1 Protein Kinase Inhibitors ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2009-04-16 US disclosed
US-20090029982-A1 PROTEIN KINASE INHIBITORS SUPERGEN, INC. (US) 2009-01-29 US disclosed
US-20080207632-A1 PROTEIN KINASE INHIBITORS SUPERGEN, INC. (US) 2008-08-28 US disclosed
US-20080207632-A1 PROTEIN KINASE INHIBITORS SUPERGEN, INC. (US) 2008-08-28 US disclosed
US-7335662-B2 Substituted tricyclic compounds as protein kinase inhibitors ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2008-02-26 US disclosed
US-7326712-B2 Substituted tricyclic compounds as protein kinase inhibitors ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2008-02-05 US disclosed
US-7326713-B2 Substituted tricyclic compound as protein kinase inhibitors ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2008-02-05 US disclosed
US-7312226-B2 Substituted tricyclic compounds as protein kinase inhibitors ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2007-12-25 US disclosed
EP-1678166-A2 PROTEIN KINASE INHIBITORS Arizona Board of Regents on behalf of The University of Arizona (US) 2006-07-12 EP disclosed
US-20050277658-A1 Protein kinase inhibitors ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2005-12-15 US disclosed
US-20050239793-A1 Protein kinase inhibitors ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2005-10-27 US disclosed
US-20050239794-A1 Protein kinase inhibitors ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2005-10-27 US disclosed
US-20050227992-A1 Protein kinase inhibitors ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2005-10-13 US disclosed
WO-2005037825-A2 PROTEIN KINASE INHIBITORS ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2005-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099165-A1 Protein Kinase Inhibitors CDK2, MAP3K1, MAP3K2 MAP2K7 218/4885AURKA 358/4885KIT 1558/4885
US-20080207632-A1 PROTEIN KINASE INHIBITORS ERBB3, ERBB2, AXL MAP2K7 175/4885AURKA 5/4885KIT 960/4885
US-20090029982-A1 PROTEIN KINASE INHIBITORS CDK2, PACSIN2, AKT1 MAP2K7 112/4885AURKA 339/4885KIT 1337/4885
US-20050227992-A1 Protein kinase inhibitors CDK2, MAP3K1, MAP3K2 MAP2K7 218/4885AURKA 358/4885KIT 1558/4885
US-20050277658-A1 Protein kinase inhibitors CDK2, MAP3K1, MAP3K2 MAP2K7 218/4885AURKA 358/4885KIT 1558/4885
US-20050239794-A1 Protein kinase inhibitors CDK2, MAP3K1, MAP3K2 MAP2K7 218/4885AURKA 358/4885KIT 1558/4885
US-20050239793-A1 Protein kinase inhibitors CDK2, MAP3K1, MAP3K2 MAP2K7 218/4885AURKA 358/4885KIT 1558/4885
US-20130302303-A1 PROTEIN KINASE INHIBITORS CDK2, MAP3K1, MAP3K2 MAP2K7 218/4885AURKA 358/4885KIT 1558/4885
US-20110212929-A1 Protein Kinase Inhibitors CDK2, MAP3K1, MAP3K2 MAP2K7 218/4885AURKA 358/4885KIT 1558/4885
US-20090143399-A1 Protein Kinase Inhibitors CDK2, MAP3K1, MAP3K2 MAP2K7 218/4885AURKA 358/4885KIT 1558/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.